These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30353794)

  • 41. Treatments for the challenging behaviours of adults with intellectual disabilities.
    Matson JL; Neal D; Kozlowski AM
    Can J Psychiatry; 2012 Oct; 57(10):587-92. PubMed ID: 23072949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Use of psychotropic agents for children with psychosomatic problems and developmental disorders].
    Ishizaki Y
    Nihon Rinsho; 2012 Jan; 70(1):130-4. PubMed ID: 22413507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychotropic prescribing in people with intellectual disability and challenging behaviour.
    Sheehan R; Strydom A; Morant N; Pappa E; Hassiotis A
    BMJ; 2017 Aug; 358():j3896. PubMed ID: 28821479
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term functional stability of problem behavior exposed to psychotropic medications.
    Cox AD; Virues-Ortega J
    J Appl Behav Anal; 2022 Feb; 55(1):214-229. PubMed ID: 34329500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective cohort study of prescription drug use among youth with intellectual/developmental disabilities in British Columbia.
    Marquis S; Marquis NE; Lunsky Y; McGrail KM; Baumbusch J
    J Intellect Disabil Res; 2024 Oct; 68(10):1156-1166. PubMed ID: 38773818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic.
    Brasić JR; Barnett JY; Kowalik S; Tsaltas MO; Ahmad R
    Psychol Rep; 2004 Dec; 95(3 Pt 2):1079-86. PubMed ID: 15762388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study.
    Song M; Ware R; Doan TN; Harley D
    J Intellect Disabil Res; 2020 Jan; 64(1):45-56. PubMed ID: 31478300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities.
    Charlot LR; Doerfler LA; McLaren JL
    J Intellect Disabil Res; 2020 Nov; 64(11):852-863. PubMed ID: 32959471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder.
    Hanson E; Kalish LA; Bunce E; Curtis C; McDaniel S; Ware J; Petry J
    J Autism Dev Disord; 2007 Apr; 37(4):628-36. PubMed ID: 16977497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.
    Doan TN; Lennox NG; Taylor-Gomez M; Ware RS
    J Intellect Dev Disabil; 2013 Jun; 38(2):177-81. PubMed ID: 23550741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polypharmacy in the treatment of subjects with intellectual disability.
    Häβler F; Thome J; Reis O
    J Neural Transm (Vienna); 2015 Aug; 122 Suppl 1():S93-100. PubMed ID: 24858727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors Associated with Developmental Behavioral Pediatricians Prescribing Psychotropic Medication to Children with Autism Spectrum Disorder: A Study of Three DBPNet Sites.
    Jackel C; Shults J; Wiley S; Meinzen-Derr J; Augustyn M; Blum N
    J Dev Behav Pediatr; 2017 Oct; 38(8):584-592. PubMed ID: 28816917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hassles with medication management perceived by caregivers of adults who have intellectual or developmental disabilities.
    Erickson SR; Yang Y
    Int J Clin Pharm; 2019 Feb; 41(1):131-140. PubMed ID: 30578472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of psychotropic medication in people with a learning disability.
    Jenkins R
    Br J Nurs; 2000 Jul 13-26; 9(13):844-50. PubMed ID: 11261057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychiatric Presentations and Medication Use in Older Adults With Intellectual and Developmental Disabilities.
    Wise E; Holingue C; Klein A; Caoili A; Charlot L; Barnhill J; Beasley JB
    Am J Geriatr Psychiatry; 2022 Jan; 30(1):65-77. PubMed ID: 34210596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving knowledge of psychotropic prescribing in people with Intellectual Disability in primary care.
    Shankar R; Wilcock M
    PLoS One; 2018; 13(9):e0204178. PubMed ID: 30216381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrative Care for Challenging Behaviors in People with Intellectual Disabilities to Reduce Challenging Behaviors and Inappropriate Psychotropic Drug Prescribing Compared with Care as Usual: A Cluster-Randomized Trial.
    de Kuijper G; Jonker J; Kouwer K; Hoekstra PJ; de Bildt A
    Int J Environ Res Public Health; 2024 Jul; 21(7):. PubMed ID: 39063526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Exploratory Study among Intellectual Disability Physicians on the Care and Coercion Act and the Use of Psychotropic Drugs for Challenging Behaviour.
    Bij de Weg JC; Honingh AK; Teeuw M; Sterkenburg PS
    Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization.
    Nøttestad JA; Linaker OM
    J Intellect Disabil Res; 2003 Sep; 47(Pt 6):464-71. PubMed ID: 12919197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The international consensus process on psychopharmacology and intellectual disability.
    Reiss S; Aman MG
    J Intellect Disabil Res; 1997 Dec; 41 ( Pt 6)():448-55. PubMed ID: 9430048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.